Perspective Therapeutics, Inc. (NYSE: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of VMT01, a targeted alpha-particle therapy (TAT), in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans.
Patients in this cohort are receiving VMT01 at 1.5 mCi in combination with nivolumab, a PD-1 blocking antibody developed and marketed by Bristol Myers Squibb as Opdivo®. Patients in earlier cohorts received VMT01 as monotherapy. Initial results from the earlier cohorts were previously presented at the 21st International Congress of the Society for Melanoma Research (SMR) in October 2024.
“The initial results from our Phase 1/2a study of VMT01 are particularly encouraging for investigating this combination," commented Chief Medical Officer Markus Puhlmann. "The data presented at the Society for Melanoma Research highlight the promising safety profile of VMT01, with no dose-limiting toxicities observed, and early signs of anti-tumor activity in patients who have received multiple lines of prior treatment. These findings provide a strong foundation for further exploration of VMT01 in combination with immune checkpoint inhibitors, where we believe its dual mechanism of action can be harnessed to improve patient outcomes.”
CATX dipped 5.5 cents, or 2.1%, to $2.52.
